{
    "nct_id": "NCT00066157",
    "title": "Alzheimer's Disease: Therapeutic Potential of Estrogen",
    "status": "COMPLETED",
    "last_update_time": "2018-08-22",
    "description_brief": "This is a 15-month study to determine the effectiveness of hormone replacement therapy in improving memory and the ability to live independently in postmenopausal women with Alzheimer's disease.",
    "description_detailed": "Estrogen is a naturally occurring hormone produced in a woman's body. The purpose of this 15-month study is to determine the effectiveness of hormone replacement therapy in improving memory and the ability to live independently in postmenopausal women with Alzheimer's disease and without other dementias.\n\nPatients who volunteer for this study will either receive a patch containing 17-\u00df-estradiol or will receive an inactive placebo patch. In addition, patients will be given either medroxyprogesterone or an inactive placebo pill. Neither the volunteers nor the study staff will know which type of patch or pill a patient receives. Patients must be generally healthy and have mild-to-moderate dementia. There must be a patient caregiver who can watch for side effects and ensure that the patient takes the study medications on schedule. Patients will undergo neuropsychological tests and an evaluation of the ability to live independently at each visit as well as laboratory evaluations, such as the taking of blood. Each visit will last approximately 3 hours. A total of 160 participants are being recruited.",
    "phase": [
        "PHASE2",
        "PHASE3"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "Cognitive enhancer",
    "drug": [
        "17-\u03b2-estradiol (transdermal estradiol patch)",
        "medroxyprogesterone (oral; used in opposed arm)"
    ],
    "placebo": [
        "placebo patch",
        "placebo pill"
    ],
    "explanation_target": [
        "Reason: The trial tests hormone replacement therapy (estrogen) to improve memory and ability to live independently in postmenopausal women with Alzheimer\u2019s disease \u2014 the stated primary goal is symptomatic/cognitive and functional improvement, not explicitly targeting core AD pathology (amyloid or tau). The intervention named in the trial is transdermal 17-\u03b2-estradiol with medroxyprogesterone as the opposed/progestin arm. \ue200cite\ue202turn0search3\ue202turn0search4\ue201",
        "Act (extracted details & sources): The public trial record (NCT00066157, \u201cAlzheimer's Disease: Therapeutic Potential of Estrogen\u201d) describes a 15\u2011month, placebo\u2011controlled study giving a patch containing 17\u2011\u03b2\u2011estradiol or an inactive placebo patch; participants also received medroxyprogesterone or placebo pill. This confirms the drug(s) and placebo used in the protocol. \ue200cite\ue202turn0search3\ue202turn0search7\ue201",
        "Act (mechanism/context): Estrogen (17\u2011\u03b2\u2011estradiol) is a small\u2011molecule steroid hormone thought to modulate neurotransmission, neuroprotection, and other brain functions; some reviews discuss potential effects on amyloid and tau in preclinical work, but clinical trials of estrogen in AD have primarily assessed cognitive/functional outcomes with mixed results. \ue200cite\ue202turn0search8\ue202turn0search9\ue201",
        "Reflect (classification rationale and uncertainty): Because the study\u2019s stated aim is to improve memory and independent living (symptomatic cognitive and functional outcomes) and the intervention is a hormone (a small steroid molecule) rather than a biologic (e.g., monoclonal antibody) explicitly targeting AD pathology, the best-fit category is 'Cognitive enhancer.' Note: there is some theoretical/ preclinical literature that estrogen may influence AD pathology (and some trials explored potential disease effects), but this specific trial design and endpoints are symptomatic/cognitive, supporting the cognitive enhancer classification rather than a disease-targeted category. \ue200cite\ue202turn0search0\ue202turn0search9\ue201",
        "Sources / web search results used for extraction and context: clinical trial listing describing 15\u2011month transdermal 17\u2011\u03b2\u2011estradiol and medroxyprogesterone vs placebo (MedPath / NCT00066157). \ue200cite\ue202turn0search3\ue202turn0search4\ue202turn0search7\ue201",
        "Additional context: randomized trials and reviews show mixed or short\u2011term cognitive effects of estrogen in women with AD and no consistent long\u2011term benefit; Cochrane/systematic reviews conclude no sustained benefit beyond a few months in dementia populations. This supports the interpretation that the intervention was being tested for symptomatic cognitive benefit rather than established disease modification. \ue200cite\ue202turn0search10\ue202turn0search2\ue201"
    ],
    "agent_type": "L) Growth Factors and Hormones",
    "explanation_agent": [
        "Reason: The trial tests hormone replacement therapy (transdermal 17-\u03b2-estradiol with oral medroxyprogesterone) to produce symptomatic cognitive/functional improvement in postmenopausal women with Alzheimer\u2019s disease. Estrogens are steroid hormones that act through estrogen receptors and modulate neurotransmission, synaptic plasticity and neuroprotection; although preclinical work shows effects on amyloid processing, the trial\u2019s stated goal and design are symptomatic/cognitive rather than explicitly targeting amyloid or tau pathology. \ue200cite\ue202turn0search4\ue202turn1search10\ue201",
        "Act: Extracted trial details \u2014 NCT record describes a randomized, placebo\u2011controlled interventional study giving transdermal 17\u2011\u03b2\u2011estradiol (patch) with medroxyprogesterone (or placebo) for treatment in AD (15\u2011month/12\u2011month regimen described in the public record). The active agents are 17\u2011\u03b2\u2011estradiol (a hormone) and medroxyprogesterone (progestin). Mechanistic literature shows 17\u2011\u03b2\u2011estradiol can modulate APP processing, reduce Abeta in preclinical models and exert neuroprotective effects via estrogen receptor signaling, but those are mechanistic/contextual findings rather than the trial\u2019s primary mechanistic claim. \ue200cite\ue202turn0search4\ue202turn1search1\ue202turn1search4\ue201",
        "Reflect: Mapping to CADRO \u2014 category L) Growth Factors and Hormones best fits because the intervention is a hormone replacement therapy (estrogen \u00b1 progestin). Although estrogen may influence AD\u2011related pathways (amyloid, tau, inflammation, synaptic function) in preclinical studies, the intervention is a hormone and the trial is aimed at symptomatic cognitive/functional enhancement rather than a focused amyloid or tau disease\u2011modifying strategy. Therefore L) Growth Factors and Hormones is the most specific CADRO category. Supporting clinical-evidence context (systematic reviews/trials) conclude no sustained cognitive benefit and point to mixed/negative findings in larger trials, reinforcing that this was tested as an HRT/symptomatic approach. \ue200cite\ue202turn0search0\ue202turn0search1\ue201",
        "Web search results used (titles + source ids):",
        "- Clinical trial registry: \"Transdermal estradiol and Medroxyprogesterone in Alzheimer Disease\" (NCT00066157 / trial registry mirror). \ue200cite\ue202turn0search4\ue201",
        "- Cochrane summary: \"Hormone replacement therapy to maintain cognitive function in women with dementia\" (Cochrane review\u2014no sustained benefit). \ue200cite\ue202turn0search0\ue201",
        "- WHIMS / HRT risk and cognition discussion (review/meta-context). \ue200cite\ue202turn0search1\ue201",
        "- Mechanistic / review literature: \"Neuroprotective Effects of 17\u03b2\u2011Estradiol\u2026\" (review of estrogen neuroprotection and receptor signaling). \ue200cite\ue202turn1search10\ue201",
        "- Preclinical studies showing estrogen lowers Abeta / affects APP processing. \ue200cite\ue202turn1search1\ue202turn1search6\ue201"
    ]
}